NEW YORK (GenomeWeb) – BG Medicine said today that its common stock will be delisted from Nasdaq effective at the opening of the Dec. 4, 2015 trading session.
The company was unable to maintain compliance with listing requirements for the exchange.
BG was notified on March 10, 2015 that its stock no longer qualified for listing on the exchange because it did not have a minimum bid price of at least $1 per share, and the company’s stockholder’s equity was not at least $2.5 million.
BG was allowed to continue listing on the exchange as it worked towards regaining compliance, though it was unable to do so. On Sept. 14, 2015, Nasdaq issued a final delisting determination, notifying BG that trading of its stock would be suspended on Sept.16, 2015.
BG did not request a review of this decision, and the decision became final on Oct. 29, 2015.
The company’s stock is now listed on the OTC market.